Candriam S.C.A. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001537014
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 653 positions · Total reported value $16.08B · Top-10 concentration 30.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 47.4% · 21 new · 252 cut · 51 exited
Active Share (vs S&P 500): 37.1% · vs QQQ: 52.6% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -0.6% · vs SPY -2.8% · Prev Value $22.00B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -1.7% · vs SPY -3.9% · Latest Value $22.25B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2024 13F filing, Candriam S.C.A. disclosed 653 equity positions with a combined reported value of $16.08B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 30.9% of reported value. HoldingsHub classifies the profile as Large / Technology Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were MSFT ($1.10B), NVDA ($848.60M), AAPL ($748.92M). By sector, the heaviest allocations are Technology 37.1%, Health Care 22.8%. Versus the prior quarter, allocation shifted toward Technology (+2.4pp), Financials (+1.2pp) and away from Other (-0.8pp), Industrials (-0.8pp).
Versus the prior quarter, Candriam S.C.A. opened 21 new positions, trimmed 252 and fully exited 51, a turnover rate of 47.4% of positions. The portfolio's overlap with the prior quarter was 86% of names.
The largest new positions opened in Q2 2024 were BMA ($43.24M), MIRM ($17.38M), AGIO ($13.92M).
Of the 51 positions fully exited versus the prior quarter, the largest were ALPN ($16.45M), BBIO ($11.75M), FOLD ($9.42M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- BMA BANCO MACRO S A · $43.24M
- MIRM MIRUM PHARMACEUTICALS INC · $17.38M
- AGIO AGIOS PHARMACEUTICALS INC · $13.92M
- ALLY ALLY FINL INC · $12.76M
- ARQT ARCUTIS BIOTHERAPEUTICS INC · $12.16M
- VRNA VERONA PHARMA ADR PLC ADR · $11.18M
- RYTM RHYTHM PHARMACEUTICALS INC · $11.14M
- ANNX ANNEXON INC · $10.06M
Fully Exited (vs previous quarter)
- ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $16.45M
- BBIO BRIDGEBIO PHARMA INC · prev qtr: $11.75M
- FOLD AMICUS THERAPEUTICS INC · prev qtr: $9.42M
- WYNN WYNN RESORTS LTD · prev qtr: $9.08M
- FDMT 4D MOLECULAR THERAPEUTICS IN · prev qtr: $8.57M
- EDU NEW ORIENTAL ED & TECHNOLOGY · prev qtr: $7.99M
- ACAD ACADIA PHARMACEUTICALS INC · prev qtr: $7.50M
- EVH EVOLENT HEALTH INC · prev qtr: $6.07M
Insider Transactions (Form 4)
Latest Candriam S.C.A. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Candriam S.C.A. is a Luxembourg-based asset management firm founded in 1989, now part of New York Life Investments, with headquarters in Strassen, Luxembourg. The firm employs a responsible investment approach integrating ESG factors across various asset classes.
Investment Approach
Responsible investment with ESG integration, combining quantitative and fundamental research, offering both active and passive investment strategies
Asset Classes
Equities, fixed income, alternatives, multi-asset solutions
Notable Facts
Part of New York Life Investments, strong focus on sustainable investing, acquired in 2018
AUM
$154.7B (SEC Form ADV regulatory figure)
Official disclosures available through SEC filings
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.46M | $1.10B | 6.82% | Hold | |
| 2 |
|
6.87M | $848.60M | 5.28% | Add | |
| 3 |
|
3.56M | $748.92M | 4.66% | Reduce | |
| 4 |
|
3.05M | $556.33M | 3.46% | Hold | |
| 5 |
|
485.62K | $439.65M | 2.73% | Add | |
| 6 |
|
2.38M | $294.69M | 1.83% | Reduce | |
| 7 |
|
1.50M | $290.07M | 1.80% | Add | |
| 8 |
|
431.66K | $238.70M | 1.49% | Add | |
| 9 |
|
450.37K | $229.34M | 1.43% | Add | |
| 10 |
|
831.37K | $218.20M | 1.36% | Add | |
| 11 |
|
200.71K | $210.94M | 1.31% | Reduce | |
| 12 |
|
610.17K | $190.64M | 1.19% | Reduce | |
| 13 |
|
1.11M | $183.69M | 1.14% | Add | |
| 14 |
|
413.19K | $182.28M | 1.13% | Add | |
| 15 |
|
951.98K | $174.60M | 1.09% | Hold | |
| 16 |
|
676.56K | $159.65M | 0.99% | Add | |
| 17 |
|
328.27K | $153.86M | 0.96% | Reduce | |
| 18 |
|
94.18K | $151.20M | 0.94% | Add | |
| 19 |
|
803.10K | $139.58M | 0.87% | Add | |
| 20 |
|
2.02M | $138.58M | 0.86% | Reduce | |
| 21 |
|
634.19K | $135.29M | 0.84% | Reduce | |
| 22 |
|
170.16K | $133.85M | 0.83% | Reduce | |
| 23 |
|
512.33K | $131.71M | 0.82% | Reduce | |
| 24 |
|
381.54K | $131.34M | 0.82% | Add | |
| 25 |
|
962.68K | $126.62M | 0.79% | Reduce | |
| 26 |
|
114.52K | $121.94M | 0.76% | Reduce | |
| 27 |
|
609.64K | $121.42M | 0.76% | Add | |
| 28 |
|
372.43K | $114.61M | 0.71% | Add | |
| 29 |
|
246.87K | $109.81M | 0.68% | Reduce | |
| 30 |
|
655.36K | $106.30M | 0.66% | Reduce | |
| 31 |
|
309.93K | $105.06M | 0.65% | Add | |
| 32 |
|
953.71K | $105.06M | 0.65% | Reduce | |
| 33 |
|
409.47K | $102.30M | 0.64% | Reduce | |
| 34 |
|
496.82K | $100.48M | 0.62% | Add | |
| 35 |
|
1.34M | $99.76M | 0.62% | Reduce | |
| 36 |
|
365.85K | $87.07M | 0.54% | Add | |
| 37 |
|
6.67M | $85.96M | 0.54% | Add | |
| 38 |
|
1.80M | $85.72M | 0.53% | Add | |
| 39 |
|
169.06K | $85.24M | 0.53% | Add | |
| 40 |
|
358.91K | $83.10M | 0.52% | Add | |
| 41 |
|
50.53K | $83.04M | 0.52% | Reduce | |
| 42 |
|
389.15K | $82.28M | 0.51% | Add | |
| 43 |
|
415.08K | $82.13M | 0.51% | Reduce | |
| 44 |
|
212.88K | $81.57M | 0.51% | Reduce | |
| 45 |
|
20.37K | $80.68M | 0.50% | Add | |
| 46 |
|
1.32M | $80.00M | 0.50% | Reduce | |
| 47 |
|
438.63K | $79.68M | 0.50% | Add | |
| 48 |
|
130.50K | $77.04M | 0.48% | Add | |
| 49 |
|
343.50K | $71.34M | 0.44% | Add | |
| 50 |
|
403.51K | $70.76M | 0.44% | Reduce | |
FAQ
What did Candriam S.C.A. buy in 2024-Q2?
In its 2024-Q2 13F filing, Candriam S.C.A. reported 653 equity positions worth $16.08B in aggregate; its largest disclosed positions were MSFT ($1.10B), NVDA ($848.60M), AAPL ($748.92M).
How large is Candriam S.C.A.'s portfolio?
Candriam S.C.A. reported $16.08B of long equity holdings across 653 positions as of 2024-Q2. Top-10 holdings account for 30.9% of reported value.
What is Candriam S.C.A.'s investment style?
HoldingsHub classifies the portfolio as Large / Technology Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.